AbbVie Raises Its Adjusted EPS Guidance For 2024 To $10.90-$10.94 From Prior Guidance Of $10.67-$10.87 Compared To Consensus Of $10.85
Portfolio Pulse from Benzinga Newsdesk
AbbVie has increased its adjusted EPS guidance for 2024 to a range of $10.90-$10.94, up from the previous range of $10.67-$10.87. This new guidance is above the consensus estimate of $10.85.
October 30, 2024 | 11:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie has raised its adjusted EPS guidance for 2024 to $10.90-$10.94, exceeding the consensus estimate of $10.85. This suggests a positive outlook for the company's financial performance.
The increase in EPS guidance indicates that AbbVie expects better financial performance than previously anticipated. This is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100